Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
IPO Year: 2019
Exchange: NYSE
Website: forhims.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $42.00 → $60.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/10/2025 | $24.00 → $25.00 | Neutral → Sell | Citigroup |
| 1/7/2025 | $35.00 | Buy | BTIG Research |
| 12/17/2024 | $42.00 | Overweight | Morgan Stanley |
| 11/14/2024 | Buy → Underperform | BofA Securities | |
| 8/22/2024 | $24.00 | Buy | Needham |
| 8/9/2024 | Outperform → In-line | Imperial Capital | |
| 5/22/2024 | $16.00 → $20.00 | Buy → Neutral | Citigroup |
| 4/16/2024 | $17.00 → $15.00 | Buy → Hold | Jefferies |
| 4/10/2024 | $20.00 | Buy | Canaccord Genuity |
MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ:RKLB) and Hims & Hers Health Inc. (NYSE:HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account. RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite launches, space exploration, and advanced aerospace systems.HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results tha
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con
The acquisition will strengthen the long-term durability of the company's domestic supply chain, helping to ensure Americans can consistently access personalized medications Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options. This press release features multimedia. View the fu
The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219392487/en/The ac
Customer-led programs give customers a leading voice in their health and wellness journey Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced two new programs dedicated to serving its customers in even more personalized ways, encouraging customers to play an active role in the decisions and choices that shape their healthcare experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204004272/en/Two new customer-led programs from Hims & Hers, the Hims & Hers Health Collective and the Hims & Hers Community Member Council, are born from the company's commitment to
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2024 financial results after the market closes on Monday, February 24, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c
Hims & Hers shares an in-depth look into how weight shapes how Americans feel about themselves, how they spend money, how it shapes culture, and more For most Americans, weight is more than just a number. It shapes our health, our mood, our confidence, our spending, and the decisions we make in our day to day lives. In fact, 75% of us think about our weight every single day, and 14% say it's constantly on our minds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212482551/en/Today, Hims & Hers unveiled The Shape of America, its end of year report on how weight loss is redefining our bodies, culture, economy and more. The re
The annual list recognizes the industry-leading companies that are the best at what they do Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, is proud to announce its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203028554/en/With a sharp focus on serving its customers, Hims & Hers continues to leverage innovative
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13D/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously
Citigroup downgraded Hims & Hers Health from Neutral to Sell and set a new price target of $25.00 from $24.00 previously
BTIG Research initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00
Morgan Stanley initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $42.00
BofA Securities downgraded Hims & Hers Health from Buy to Underperform
Needham initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $24.00
Imperial Capital downgraded Hims & Hers Health from Outperform to In-line
Citigroup downgraded Hims & Hers Health from Buy to Neutral and set a new price target of $20.00 from $16.00 previously
Jefferies downgraded Hims & Hers Health from Buy to Hold and set a new price target of $15.00 from $17.00 previously
Canaccord Genuity initiated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $20.00
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
S-8 - Hims & Hers Health, Inc. (0001773751) (Filer)
10-K - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con
The acquisition will strengthen the long-term durability of the company's domestic supply chain, helping to ensure Americans can consistently access personalized medications Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options. This press release features multimedia. View the fu
The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219392487/en/The ac
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2024 financial results after the market closes on Monday, February 24, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c
Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024 Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Improving momentum in both the Hims and Hers brands delivered another strong qu
Hims & Hers Health, Inc. ((", Hims &, Hers", , NYSE:HIMS), the leading health and wellness platform, today announced that it will report third quarter financial results after the market closes on Monday, November 4, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to
Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredibl
Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management tea
Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2024 in a shareholder letter that is posted at investors.hims.com. "We are pleased to begin the year with exceptional results and strong momentum throughout the busines
Hims & Hers Health, Inc. ((", Hims &, Hers, ", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2024 financial results after the market closes on Monday, May 6, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Former FDA deputy commissioner and former Pfizer & Hillrom quality executive join Hims & Hers, deepening the leadership that drives the company's high standard of quality and safety Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality,
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com
Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722754740/en/Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Pho
Manuel joins Hims & Hers board of directors to help the company further innovate and increase access to healthcare for millions within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official. This press release features multimedia. View the full release here: https://www.businesswire.com
Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403772620/en/Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space. (Photo: Business Wire) "Christopher brings extensive experience working dir
Dr. Daniel Lieberman was previously a Clinical Professor of Psychiatry and Behavioral Sciences at George Washington University Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform on a mission to help the world feel great through the power of better health, today announces a key leadership appointment, naming psychiatry and behavioral sciences industry veteran Dr. Daniel Lieberman, M.D., as the company's Senior Vice President of Mental Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005429/en/(Photo: Business Wire) In this role, Dr. Lieberman will oversee the psychiatry and
Dr. Scott Knoer was previously Chief Pharmacy Officer at Cleveland Clinic & CEO of the American Pharmacists Association Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, today made a key leadership appointment, naming pharmacy industry veteran Dr. Scott Knoer, Pharm.D., MS, FASHP, as the company's first-ever Chief Pharmacy & Innovation Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005225/en/Dr. Scott Knoer, Chief Pharmacy & Innovation Officer at Hims & Hers (Photo: Business Wire) In this